Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability

Diabetes Care. 2011 May;34 Suppl 2(Suppl 2):S279-84. doi: 10.2337/dc11-s231.
No abstract available

Publication types

  • Review

MeSH terms

  • Diabetes Mellitus, Type 2 / drug therapy*
  • Exenatide
  • Glucagon-Like Peptide 1 / adverse effects
  • Glucagon-Like Peptide 1 / agonists*
  • Glucagon-Like Peptide 1 / analogs & derivatives
  • Glucagon-Like Peptide 1 / therapeutic use
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use*
  • Liraglutide
  • Peptides / adverse effects
  • Peptides / therapeutic use
  • Venoms / adverse effects
  • Venoms / therapeutic use

Substances

  • Hypoglycemic Agents
  • Peptides
  • Venoms
  • Liraglutide
  • Glucagon-Like Peptide 1
  • Exenatide